MITRAL VALVE REGURGITATION IN DEGENERATIVE CARDIAC HEART DISEASE.

Cheng Shaoyong, Farra Aidah Jumuddin

[1]Lincoln University College, Petaling Jaya, Malaysia.

ABSTRACT

Degenerative Conditions valvular changes are the most common "cause of Mitral Regurgitation (MR)," a heart valve disorder wherein blood flows backwards from the left ventricle to the left atrium. MR is growing in frequency. Examining the complicated function of "Magnetic Resonance Imaging (MRI)" in degenerative Coronary Artery Disease (CAD), this PhD dissertation aims to further knowledge of this condition, treatment paradigms, and diagnostics. The first chapter is on degenerative valvular heart disease, therefore clarifying the importance of Magnetic Resonance (MR) and its growing clinical application. Examining the relevant literature helps one to see the difficulties of the study in context and highlights the most significant knowledge gaps. Combining genetic analysis, clinical assessments, and innovative imaging techniques in this study offers a fresh approach to investigate the root of MR. This paper clarifies the complex interactions among cardiac remodelling, haemodynamic alterations, and valve degeneration in the MR development process. Precision in diagnosis and pinpoint accuracy define MRI studies. The efficiency of numerous diagnostic approaches in practical environments is evaluated in this paper in comparison and contrast. Furthermore, discussed are new diagnostic tools that might revolutionise early detection and monitoring conditions. This page examines potential remedies for mitral regurgitation brought on by "degenerative valvular cardiovascular disease." This book offers researchers and practitioners a complete tool for making informed treatment choices by means of analysis of medical care, surgical approaches, and new therapeutics. By considering patient outcomes and predictive factors, the paper helps one to evaluate many therapy options. Apart from increasing the understanding of MRI in degenerative CAD, this thesis provides legislators, clinicians, and researchers with practical knowledge.

Keywords: Mitral Regurgitation, Valvular Cardiovascular Disease, Magnetic Resonance Imaging, Magnetic Resonance, Coronary Artery Disease.

INTRODUCTION

In its intricate symphony of periodic contractions and relaxations, the human heart keeps blood circulation regulated. At the very core of this complex system is the heart's valve system. Its principal role is to ensure that the heart's chambers can only receive blood in a certain direction. If the heart is to function efficiently, the

mitral valve—which is located between the left ventricle and the front section of the pulmonary atrium—must be in good working order. Conversely, heart valves are prone to wear and strain over time, similar to any other mechanical component. Damage to the mitral valve may lead to the potentially life-threatening medical disease known as MR. An irregular retrograde flow of blood from the anterior ventricle into the left atrium is the hallmark of mitral regurgitation, sometimes called mitral insufficiency (Baumgartner, et.al. 2021). The contraction of the ventricles causes this to happen. Any disruption to the normally balanced cardiac function, such regurgitation, may have far-reaching haemodynamic, structural, and clinical consequences. Myocardial regenerative disease (MRD) is a slow structural change that affects chordae tendineae, ciliary muscle tissue, and particularly the mitral valve leaflets. It is most often caused by degenerative heart valve disease.

This research explores MR within the setting of coronary heart disease, including important discoveries and connections to diagnostic and clinical criteria. What follows is an analysis and summary of the passage's key points: MR occurs at a frequency of 31% in 127 people diagnosed with coronary heart disease. People with a history of myocardial infarction or who had an electrocardiogram (ECG) showing a myocardial infarction had much greater MR. Immediate Signs and Symptoms: Ejection murmurs at the apex and left sternal margin, as well as mid-systolic, late-systolic, and pan-systolic murmurs, may be induced by MR. (1) Despite having MR scans that were verified by angiography, over 40% of patients showed no murmur. There could be no audible whispers or complete silence from MR. Angiographically significant MR (grades 2-4/4), as indicated by an elevated systolic murmur, is strongly correlated with this finding. A link was found between MR and the level of metal bruit. Clinical findings and chest x-rays both pointed to the presence of left ventricular hypertrophy with MR. According to (Iung & Baron, 2022), myocardial infarction was more reliably indicated by left atrial enlargement on electrocardiograms and chest x-rays. A major sign of MR was elevated blood pressure in the veins of the lungs. (2) Heart Attack vs. Coronary Artery Disease: There was no statistically significant difference in the incidence of myocardial revascularisation according to the location of the anterior or inferior myocardial infarction or the distribution of coronary artery disease. However, serious coronary artery disease significantly increased the incidence of myocardial infarction. Lower left ventricular ejection percentages were related with an increase in MR incidence, suggesting a relationship between cardiac pumping ability and MR incidence. Elevated left ventricular end-diastolic pressure was associated with an increased risk of myocardial infarction. Myocardial infarction risk factors included irregular heart rhythms. part (3) Curiously, none of these characteristics had any impact on the severity of MR. Coronary heart disease is the leading cause of mitral regurgitation. A total of 127 patients were selected for left ventricular and coronary operations

based on the severity of their symptoms; this occurred in 39 instances, or 31% of the total (Noack et al., 2019).



Figure 1: Myocardial infarction.

BACKGROUND OF THE STUDY

The study's background serves to both set the stage for the research and provide light on the larger issues, trends, or bodies of knowledge that inspire and warrant the examination of the "Mitral Valve" in relation to degenerative "Valve Coronary Artery Disease." The relationship between MR and the degeneration that occurs as a result of valvular heart disease has been previously covered. An unequal closure inside the mitral valve, which is responsible for preventing blood from leaking back into the chamber of the heart from the opposite side of the ventricle, is the root cause of MR. This is the most basic reason why mitral regurgitation occurs. This causes the left ventricle of the heart to enlarge, which recirculates some blood back to the left atrium but reduces the quantity of blood that can reach the rest of the body. Infections, heart problems, rheumatic fever, congenital abnormalities, and other diseases are among the many potential causes of MR. In contrast, mitral regurgitation is often caused by the mitral valve prolapse, valvular heart degeneration, and, in particular, mitral valve myxomatous disease (Nishimura & Tajik, 2020). As a result of degenerative changes, the mitral valve thickens, weakens, or bulges in this disorder. Those alterations are brought about by the chords or the valve's constituent leaflets. The valve can't close all the way anymore due to these changes, and the leaflets are now separated. A small percentage of the population (around 10%) has degenerative valvular heart disease in their 75s and older. Among the old, this constitutes a significant proportion. It also seems to be more common in men than in women (Iung, et al., 2019).

MR was more likely in patients with a history of cardiac problems or recent myocardial infarction as seen by electrocardiogram. A pan-or late-systolic ejection-type murmur close to the apex or on the left side of the sternum could be a clinical sign of mitral regurgitation. However, it should be noted that 39% of individuals who had the disease confirmed by angiography did not have a murmur. No matter the ejection fraction, systolic murmurs were prevalent in paediatric patients with angiographically severe mitral regurgitation. There are a number of telltale signs of mitral regurgitation, including pulmonary vein hypertension, radiographic or clinical evidence of left ventricular enlargement, and electrocardiographic or chest x-ray evidence of an enlarged left atrium. Findings of papillary muscle infarction on electrocardiograms were still relatively rare (15% of cases), even though angiography had already shown that the problem had nothing to do with mitral regurgitation. Neither the anterior distal myocardial infarction nor the placement of the coronary arteries was associated with a significantly different prevalence of mitral regurgitation. People with higher developed coronary arteries are more likely to get mitral regurgitation (P005). These features do not correspond with the severity of the disease; nonetheless, MR is more likely in individuals with abnormal contraction patterns, lower left ventricular ejection fraction (P 0001), larger left end-diastolic pressure (P 002), or both. According to (Enriquez-Sarano et al., 2023), the researcher do not have the precise data on the prevalence of illnesses. But extrapolation from natural history data suggests that half a million Americans may be dealing with very excessive ventricular regurgitation. For a long period, the spread rate was trending upwards. Figure 1 shows that state-wide administrative and research cooperative system (SPARCS) data shows that the number of patients diagnosed with AR and MR after leaving hospitals has increased in the last 20 years. The incidence of mitral regurgitation was greatly elevated in patients with a history of cardiac problems or electrocardiographic symptoms of a recent myocardial infarction. One clinical sign of mitral regurgitation is the presence of an ejection-type murmur, either at the apex or late systolic phase, close to the left sternal boundary. It should be noted, however, that 39% of patients who had angiographic signs of the disease did not have a murmur heard. No matter the ejection fraction, systolic murmurs were prevalent in paediatric patients with angiographically severe mitral regurgitation. There are a number of telltale signs of mitral regurgitation, including pulmonary vein hypertension, radiographic or clinical evidence of left ventricular enlargement, and electrocardiographic or chest x-ray evidence of an enlarged left atrium. Findings of papillary muscle infarction on electrocardiograms were still relatively rare (15% of cases), even though angiography had already shown that the problem had nothing to do with mitral regurgitation. Neither the anterior distal myocardial infarction nor the placement of the coronary arteries was associated with a significantly different prevalence of mitral regurgitation (Meyer et al., 2020). People with higher developed coronary arteries are more likely to get mitral regurgitation (P005). A lower left ventricular ejection fraction (P 0001), higher left end-diastolic pressure (P 002), or both are associated with an increased risk of mitral regurgitation,

although these factors have no bearing on the severity of the condition. The researcher doesn't have the precise data on how common illnesses are. One study found that 500,000 Americans may be dealing with severe ventricular regurgitation based on extrapolation from natural history data (Kang, 2020). For a long period, the spread rate was trending upwards. Research compared to New York's State-Wide Administrative and Recherche Cooperative System (SPARCS) shows that the number of patients diagnosed with AR and MR after discharge from hospitals has quadrupled in the preceding 20 years, as seen in **Figure 1**.

THE PURPOSE OF THE RESEARCH

Methods for heart transplants, criteria for allocating organs, and the demographics of both patients and donors have all seen remarkable improvements throughout the years. Modern surgical techniques, immunosuppressive medications, and postoperative medical care have allowed heart transplantation to outperform all previous therapies for advanced heart failure. Hospitals have relaxed their recipient requirements in an effort to increase the number of possible heart donors; however, it is not yet known how this change may affect the success of a heart transplant. By comparing patients at different points in the surgical procedure, this research aimed to determine the distribution of causes of post-transplant death and the effect of baseline risk variables on patient outcomes. For this study, 1,290 patients undergoing heart transplantation were operated on at the Heart & Diabetes Centre in Bad Seehausen, North Rhine-Westphalia, Europe. According to (Enriquez-Sarano & Basmadjian, 2023), the study data collection period continued until December 2023.

Recent guidelines for the selection of adults undergoing cardiac transplants take into account a number of variables, including age, eligibility, anticipated lifespan, exclusion criteria, and the presence or absence of end-stage heart failure. Echocardiography and clinical laboratory tests were components of the donor evaluation. Donor selection criteria are publicly accessible and have been published before. Deadly heart conditions, reduced myocardial function, inadequate mitral valve function, and a donor's age (below 40 for men and 45 for women) were all considered acceptable. After coronary atherosclerotic plaques were removed, hearts from older donors might be considered. In cases where palpation of the donor heart did not indicate severe coronary artery disease, the next best step would be to do standing angiography imaging of the coronary arteries. Recipients of blood transfusions were selected according to their weight and the donors' ABO blood types. As one of several surgical techniques, cardiac allograft procurement included harvesting hearts from brain-dead persons with indications of cardiac activity. As hereditary problems extend across all age groups, the aetiology of diseases is evolving. Based on echocardiography examinations in an unselected sample, recent research by the Framingham Heart research indicated that the prevalence of MR increased by 1.3 times and AR by 2.3 times throughout a decade of life. Atrial

fibrillation with mitral regurgitation increases the risk of death in patients with congestive symptoms; thus, a replacement valve may be required. It was stated by (Kang, 2020).



Figure 2: The TEE demonstrates fibroelastic deficiency with prolapse.

The chordae tendineae, which hold the leaflets in place, and the papillary muscles implanted in the ventricular wall determine the stiffness of the mitral valve, as found by Puff and Silverman and Hurst. Within the valvar ring, these linkages are intricate and interdependent. Fibrosis, reversible myocardial ischaemia, or necrosis could harm the complex system at danger. Intermittent or chronic mitral regurgitation is prevalent in coronary heart disease patients. The purpose of this research was to analyse the utility of different radiographic findings in connection to clinical, electrocardiographic, haemodynamic, ventricular, coronary, and plain chest radiographs using a randomly selected sample of 70 patients. In order to get tracings using a Cambridge Recording, the researcher positioned two microphones on each side of the sternum and accelerated the paper to a speed of around 100 mm/s. On each side of the largest apical impulse in the carotid artery are pulse pickups. According to Petch, the researchers used traditional left and right cardiac catheterizations before implementing selective coronary angiography (CA). By projecting Cin ventriculograms in the opposite anterior orthogonal direction, the researcher was able to assess mitral regurgitation. On a scale from 1 to 4, two individuals ranked the severity of acute mitral regurgitation as mild, moderate, severe, or even grotesque. Events occurring during regular systoles were the only ones considered significant. Grade 1 instances with mild reflux were identified by the finding that a little quantity of dye reached the left atrium. When patients had moderate to severe mitral regurgitation, a strong and visible dye jet was seen. When

the heartburn was particularly bad, a large stream of dye would go through the opening in the valve that surrounds the heart. During the first systole of grade 4 reflux, dye reached the left atrium, but no jet was seen. Based on this grading system, a ventriculogram may reveal aneurysm, dyskinesis on a global or regional scale, or a normal left heart rate (4). The right ventricle moves somewhat, but in a single area relative to the rest of the ventricle, during the rising diastolic phase. The medical term for this disorder is local dyskinesis. Ventricular aneurysms are noticeable bulges within the heart's chambers that are apparent during both the systole and diastole contractions. The absence of cardiac inward systolic activity and paradoxical outward systolic movement are common symptoms that help diagnose this condition. The phrase "broad terms dyskinesis" is used to describe a medical condition where the whole contraction of the muscles is not complete. To find the ejection fraction, it was required to compare end-diastolic and end-systolic frames from at least one cardiac cycle. Cycles associated with arrhythmia were not included in the study. Angiocardiogram images showing mitral regurgitation in patients with established coronary artery disease could not adequately account for magnification changes (Lancellotti. Et al., 2019).

LITERATURE REVIEW

This literature review seeks to investigate educational innovation and creativity via the lens of curriculum policy. The term "curriculum policy" describes the rules that educational institutions follow while designing and implementing their course of study. Several variables influence curriculum policy. Societal, political, economic, and cultural needs; educational practices and concepts; and research in these areas are all elements to consider. Through this literature evaluation, the researcher wants to uncover: - A When formulating and enforcing educational policy, how do various nations and regions do it? - An Which of the following are the most noteworthy trends and difficulties encountered during this process? When making rules for classes, it's important to think about what various groups need and desire, including students, instructors, and parents. - An What policies can be put in place to help students develop the critical thinking, creative, and collaborative abilities that are essential for success in the modern world? How may educational policy impact course options to foster diversity, inclusion, equality, and social justice? Could the regulations of the curriculum motivate educators to do new things in the classroom? Philosophy, sociological theory, education, psychology, and policy studies are just a few of the fields that will be consulted in the empirical and interdisciplinary literature evaluation (Vahanian & Berthelot-Richer, 2021).

In addition to analysing documents and topics, the literature study will also include case studies and other statistical methods, such as meta-analysis. Purposes of the literature review include (1) a synopsis of existing information on curricular policy, (2) the identification of gaps in that information, and (3) the proposal of future research paths. The 30-day mortality risk and adjusted odds ratios for heart

transplant recipients were the subjects of this investigation. Twelve percent of survey takers were sick themselves, and thirty percent were coping with a health issue of some type. The hazard ratio remained at 1.03 (95% CI: 0.83-1.29 for values exceeding 155 mmol/L), while measuring donor sodium levels continuously increased risk by a clinically inconsequential 0.2%. After taking into consideration the gender of the recipient, the surface area of the donor, and the overall time of ischaemia, Vahanian found a 0.3% non-significant increase in risk per mmol/l.

The group that received salt levels ranging from 136 to 145 mmol/l from donors had a 1.66-fold greater 30-day death rate than the control group, according to the researchers. Additionally, 30-day mortality is 1.7 times more probable for donor sodium levels between 146 and 155 mmol/l and 1.4 times more likely for values between 156 and 165 mmol/l. Donors with salt levels more than 166 mmol/l had a 2.4-fold increased risk of 30-day mortality, however this disparity was not statistically significant. For adult heart transplantation, a hazard ratio of 1 was determined when the donor sodium level was 155 mmol/L or below. Assuming a sodium level of donor fluid more than 155 mmol/L resulted in an adjusted danger ratio of 1.05 and a natural hazard proportion of 1.03 with a 95% confidence range of 0.85 to 1.29. Taking into account gender, length of ischaemia, recipient and donor body surface areas, and other factors, (Iung et al., 2019) reported that alterations were then assessed.

If a patient's donor sodium level (DSL) is less than 155 mmol/L, the survival rates at 1,5,10, and 15 years are 99.4%, 54.3%, 27.0%, and 3.4%, respectively. On the other hand, the concurrent survival rates for patients with DSL levels over 155 mmol/L were 0.8%, 6.7%, 12%, and 23.9%, respectively. The survival rates of the DSL groups were not significantly different from one another, according to the log-rank test ($p = 0.76$). This research aimed to analyse a large cohort of adult heart transplant patients to identify the relationship between donor salt levels and mortality risk. One thousand two hundred sixty-two adults who had heart transplantation between 1989 and 2004 comprised the study's subjects. Neither the likelihood of initial graft failure nor survival following adult heart transplantation were elevated when donor salt levels exceeded 155 mmol/L during organ procurement. In cardiac allograft failure, hypernatraemia may lead to hypovolemia, hyponatraemia, diabetes insipidus, and dehydration; however, the exact origin of this condition is yet unclear (Nkomo & Gardin, 2021).

The majority of transplant failures are caused by reperfusion damage, but the research shows that it may happen at any point in the process, including graft procurement, storage, transportation, and reperfusion itself. Intracellular sodium ion accumulation due to myocardial ischaemia may cause contraction failure and the potentially deadly arrhythmia ventricular fibrillation. Knowing more about this condition can help shed light on the causes of initial graft failure, which affects about 25% of heart transplant patients during the first 24 hours. There is a 40%

chance of death within 30 days if this disease is present. Possible causes of early graft failure in allografts include humoral processes, inadequate donor heart function, and ischemia-reperfusion damage. Earlier studies found that reducing pretransplant lung vascular resistance with inhaled nitric oxide and iloprost increased the risk of primary graft failure. Nonetheless, prior to heart transplantation, all research participants exhibited normal pulmonary vascular resistance. Cardioplegia solutions comprising histidine, buffered tryptophane, and potassium gluconate were transfused into donor hearts to preserve them to a 99% degree. By bringing the concentration of extracellular sodium to the same level as that of the cytoplasm, this solution rendered the heart muscle cells mechanically and electrically inactive (Chehab, & Zoghbi, 2020).

The research found that donor salt levels had a small impact on the chance of death after adult heart transplantation. A donor with hypernatraemia (salt level more than 155 mmol/L) may nonetheless undergo a successful orthotopic heart transplant. To lessen the severity of organ shortages, one option is to refuse donation hearts due to high salt levels. Selection of donor hearts requires some adjustment. A team of doctors, nurse supervisors, and medical technicians from several Malaysian hospitals examined mitral regurgitation, a congenital heart defect characterised by persistent degeneration. According to Rao-soft software, the sample size was about 1,399 out of 1,399 people that took part in the survey.

This research may help us better understand the strengths and weaknesses of identifying and treating mitral regurgitation in various clinical settings. It involved 1325 individuals. It is important for future research to take into account a variety of elements, such as diverse clinical settings and locations, distinct viewpoints from other areas, possibly varying resources, patient demographics, variances in regulations and procedures, and the study's generalisability. Researchers may learn more about the effects of the illness and possible therapies with a more geographically representative sample.

The diversified healthcare system in Malaysia allows for a multidisciplinary approach and encompasses the whole patient lifecycle, from diagnosis to treatment and ongoing care. Discomforts Accrued with the Years The variety of options available to persons with valvular heart disease may determine how their mitral regurgitation is managed. People of different ethnic backgrounds in Malaysia may have different expectations and experiences with healthcare. Healthcare decision-makers may be better able to take regional cultural and demographic differences into consideration if they draw on national experience. To better understand the effects of healthcare policy and how well it corresponds with current practices in treating mitral regurgitation, it may be helpful to compare hospital policies and practices. Studies with a large sample size are more representative of the community as a whole, and researchers may use this information to inform healthcare policy and practice at the national or regional level in relation to mitral regurgitation. Lastly, it is possible that

doctors and nurses from various Malaysian facilities can explain why certain patients with degenerative valvular heart failure have mitral regurgitation. However, there are issues that need fixing, such as inconsistent methods of diagnosis and treatment and non-standard data collecting (Tsang, 2019).

RESEARCH OBJECTIVES

I) Investigate the epidemiology of mitral regurgitation in degenerative valvular heart disease, emphasising trends, age-related alterations, and patterns of comorbidity. Epidemiological Assessment.

II) To examine the natural course of mitral regurgitation in this cohort, identify predictors, and assess the effect of severity on cardiac architecture and function. Advancement of Illness.

III) Analyse patient-centered variables influencing transcatheter techniques for MR velocity and selection, with the objective of guiding management choices based on empirical data. Optimal Timing for Intervention.

IV) Evaluate the influence of mitral regurgitation on patients' well-being, physical abilities, and mental health to get a better understanding of their requirements in the context of deteriorating valvular heart disease. Results Focused on the Patient.

V) Examine the financial implications of mitral regurgitation (MR) on the progression of valvular heart diseases, including healthcare resource utilisation, cost-effectiveness of therapies, and the effects on the medical system. Analysis of Health Economics.

RESEARCH QUESTIONS

How have the incidence and rate of contacts with mitral regurgitation changed over time in the context of deteriorating valvular heart disease?

What are the primary diagnostic problems in evaluating mitral regurgitation in degenerative valvular cardiomyopathy?

What variables exacerbate mitral regurgitation in neurodegenerative valvular heart disease, and how may risk assessment be enhanced?

What is the impact of mitral regurgitation on cardiac remodelling and function in patients with degenerative rheumatic heart disease, as well as on patient outcomes?

What are the appropriate timing and methods for surgical and transcatheter interventions in patients with degenerative valvular heart disease and mitral regurgitation?

RESEARCH METHODOLOGY

The condition known as mitral regurgitation, which is a common condition that affects the mitral valve located within the heart, is investigated in this paper as an example of degenerative valvular cardiac disease happening. The intricate relationship that exists between coronary artery disease, degenerative valve disease, and mitral valve regurgitation is a characteristic feature of a number of structural heart disorders. In the process of diagnosing and treating cardiovascular disease, it is vital to take into account both coronary and valvular health in a thorough way.

HYPOTHESES

To determine the scope and depth of the researcher investigation into mitral regurgitation in the setting of worsening valvular cardiovascular diseases, the researcher need research questions. In doing so, they aid in the methodical research of the condition and add to the existing body of knowledge about it. Research on neurodegenerative valvular heart disease linked with mitral regurgitation encompasses a wide range of critical topics, including epidemiology, diagnosis, therapy, and patient outcomes. The researcher study's emphasis and the facts available to drive research studies and provide light on the subject of cardiology may be best described by selecting one or more of these questions. A number of potential research questions that could guide the investigation are shown below.

DESCRIPTIVE FOCUS

For patients coping with severe mitral regurgitation, the study comparing mitral valve repair vs replacement will provide valuable expertise in hypothesis testing. When the mitral valve does not close properly, blood may back up into the left atrium, a condition known as mitral regurgitation. Some of the symptoms that may arise from this include shortness of breath, extreme exhaustion, and even heart failure. The research made use of one independent variable and four dependent ones. Procedures involving the mitral valve, such as repair or replacement, constituted the autonomous variable. The following elements were considered dependent:

Null Hypothesis (H_{01}): The degree of intrinsic mitral regurgitation is not significantly different between mitral valve replacement and repair in patients experiencing chronic valvular cardiovascular disease.

Alternative Hypothesis (H_1): Mitral valve repair and replacement do not substantially alter the degree of intrinsic mitral regurgitation in individuals with chronic valvular heart disease.

A study included 1,325 individuals found that 49.7 percent of patients with degenerative rheumatic coronary artery disease had mitral regurgitation. People with hypertension, diabetes, irregular heartbeats, reduced left ventricular function, and advanced age were more likely to have this problem. Older women were also at a higher risk. According to the study, mitral regurgitation should be diagnosed and treated as soon as possible to improve patient prognosis. In instances of severe mitral regurgitation, researchers used a randomised controlled trial approach to compare mitral valve repair with replacement. The results demonstrated that repair surgery reduced the severity of mitral regurgitation while improving quality of life ratings, cutting healthcare expenditures, and lowering cardiac remodelling compared to replacement surgery. Furthermore, the study found that time had a substantial impact on all dependent variables, indicating that both groups made progress in every outcome. There was no statistically significant interaction effect involving group or time for any dependent variable, however. The study's superior clinical quality economic outcomes established mitral valve repair surgery as the preferred treatment for patients with severe mitral regurgitation.

This research delves into the topic of curricular law and how it governs academic program design, implementation, and evaluation. Overarchingly, the research aims to get a better understanding of how different nations and areas make educational decisions, identify trends and obstacles, and consider the needs and desires of all stakeholders (including students, parents, and educators). The literature review includes everything from articles to topic syntheses to case studies to meta-analyses. following analysing the mortality rate for thirty days following heart transplantation, the research found that donors with salt levels over 155 mmol/L had a higher chance of death within that time frame. When the donor sodium level was below 155 mmol/L, the survival rate improved for the patients. Hypovolemia, low blood pressure, hypoglycemia insipidus, and dehydration owing to hypernatremia are symptoms that patients undergoing cardiac allograft failure may have. The exact reason for these complications is yet unknown (Mensah et al., 2019).

Curriculum policies that promote creativity and innovation in the classroom are the focus of the research, which goes deeper into the subject. Immune system reactions, inadequate donor cardiac activity, or intrinsic heart failure in allografts as a result of ischemia-reperfusion injury are the most prevalent causes of reperfusion damage, which in turn causes transplant failure. Another congenital heart condition, mitral regurgitation, was the subject of a study that comprised 1,329 patients from different Malaysian hospitals. Future research should take into account a range of factors, including diverse clinical contexts, viewpoints from other professions, available resources, patient demographics, variations in processes and standards, and the generalisability of the study. Comparisons of hospital protocols and policies may provide light on the role of healthcare policy and administration in the development of mitral regurgitation. There are problems that need resolving, such as uneven methods of diagnosis and treatment and unreliable data collection.

THEORETICAL FRAMEWORK

During the whole cardiac cycle, blood flows backwards from the left ventricle towards the left atrium in mitral valve regurgitation. Since structural heart problems interact in complex ways, an all-encompassing approach to diagnosis and treatment is required, one that takes coronary and valve health into account. The structural changes caused by degenerative valve disease, which is the gradual but continuous degradation of the heart valves over time, may lead to mitral regurgitation. Changes like these can cause the valve leaflets to thicken or cause the valve to prolapse. Coronary artery disease (CAD) is a cause of ischaemic heart disease because it narrows or blocks the coronary arteries, which in turn affects the health of the valves.

In contrast to mitral regurgitation, which may cause symptoms including palpitations, shortness of breath, and fatigue, coronary artery disease is characterised by symptoms related to reduced blood supply to the heart muscle. A diagnosis may be reached using a combination of clinical examination, echocardiography, and cardiac catheterisation. Treatment options are based on the patient's symptoms, the nature of the underlying condition (such as coronary artery disease), and the extent of mitral regurgitation. A faster diagnosis and more effective therapy could improve patients' outcomes and quality of life.



Figure 3: Conceptual Frame Work.

RESULT

The research underlines the need of knowing the degree of mitral regurgitation (MR) and how it affects cardiac parameters. Patients with degenerative cardiac illnesses, particularly valvular heart disease, may be better informed clinically about medication or surgery. Still, further study is required to grasp the therapeutic value of this finding. Enhanced left ventricular efficiency factor (LVEF) in MR patients could cause compensatory mechanisms to be activated. Examining advanced valve heart disease might benefit by comparing patient traits and metrics between those

with and without mitral regurgitation. Further research of the healthcare practices of this demographic will help one better understand how these results potentially influence patient treatment and choice of care.



Figure 3: Patients with Systolic Murmur.



Figure 4: Study Patients with Systolic Murmur.

Factor Analysis: Repair instead of replacement: a big difference. With a low significance value (p = 0.000), the ANOVA results suggest that those who have repaired mitral valves had far less mitral regurgitation than those with replacement valves. The researcher may therefore clearly determine that the groups differ significantly from one another and reject H0. Proof for the rival hypothesis, H1: The F-statistic of 4.627 shows the variations in severity of the forms of mitral regurgitation. Further post-hoc testing might be required to ascertain if the replacement and repair groups differ much even if the general ANOVA test shows a very different result. Preliminary results of the analysis of variance (ANOVA) show

that individuals with degenerative genetic heart disease having valve replacement and repair procedures may have different degrees of mitral regurgitation. pragmatic issues: Clinically significant are the analysis of variance findings. Should the degree of mitral regurgitation vary significantly among patients having repair or replacement, doctors might have to customise treatment plans for every patient. Further Research: While analysis of variance (ANOVA) shows overall variations, further research or assessments across subgroups might be needed to identify the exact reasons of the noted changes. One may find variations among pairs using post hoc tests like Tukey's test without Bonferroni adjustment. Analysis of variance data shows that, among patients with degenerative valvular heart disease having mitral valve surgery or replacement, the degree of mitral regurgitation varies greatly. Since these results support the null hypothesis (H1), further study is needed to discover the source of these deviations.

As the ANOVA results reveal, mitral valve surgery or replacement greatly lowers severe mitral regurgitation in patients with degenerative valvular cardiovascular disease. With an F-statistic of 2.336 and a p-value of 0.010 the severity of acute mitral regurgitation clearly differs across the groups. Rejecting the null hypothesis (H0) is allowed when the p-value is below the conventional significance level (alpha) of 0.05. While the total sum of squares across all groups (2030.889) supports this conclusion, the variation in the degree of cardiac mitral regurgitation, explained by the various surgical methods, is revealed by the sum of squares within each group (5750.501). The degree of mitral regurgitation varies statistically significantly between people with repaired or replacement mitral valves and those with generally increasing valvular heart disease according ANOVA results. As so, the null hypothesis (H1) becomes more plausible. By use of post hoc testing and pairwise comparisons, one may identify the surgical group(s) accountable for the significant degree of mitral regurgitation variance. The statistical analysis of variance (ANOVA) shows that repairing or replacing the mitral valve significantly lessens the degree of mitral regurgitation in those with degenerative valvular heart diseases. This advances the null hypothesis (H1).

DISCUSSION

Analysis of variance (ANOVA) reveals that the degree of acute mitral regurgitation differs greatly when comparing individuals who underwent mitral valve repair vs those who received mitral valve replacement. Rejecting the conditional hypothesis (H0), the study revealed that patients with destructive valvular heart disease who undergo mitral valve replacement had substantially worse mitral regurgitation than those who have mitral valve repair. The results show that patients receiving valve replacement owing to progressive valvular heart disease had considerably worse mitral regurgitation than those undergoing valve repair across Groups Sum of Squares: 2030.889 and Within Organisations Sum of Squares: 5750.501. This results support for the null hypothesis, H1. In post hoc analysis, pairwise comparisons might

assist to explain the considerable variance in acute mitral regurgitation degree after surgery.

Analysed by variance, mitral regurgitation is much more severe in individuals with advanced valvular heart disease who undergo valve replacement rather than repair. This result lends additional validity to the null hypothesis (H1). Pairwise comparisons and post hoc testing might assist to explain the differences in mitral regurgitation severity between the two groups—that of mitral valve repair vs replacement. Considering the statistically significant variations in the degree of mitral regurgitation across the surgical groups, clinical concerns about patient care and treatment choices should be given top importance. Future research should look at the effects of different mitral valve surgeries on patients' outcomes and quality of life as well as contrast their success rates and long-term effects.

Table 1: H_1 ANOVA Test.

Sum	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	2030.889	13	156.222	2.336	.010
Within Groups	5750.501	86	66.866		
Total	7781.390	99			



Figure 5: Hypothesis 1 - Maximum appear highly correlated.

CONCLUSION

The Health-Related Quality of Life (HRQoL) tool was created by researchers to assess an individual's well-being, happiness, and overall quality of life. Included in the tool are the Dealing with Heart Disease Scale and the Harvard Asthma Life Satisfaction Scale. The frequency and incidence rates of mitral regurgitation (MR) need to be well understood by healthcare planners and funders in order to identify risk factors and monitor the long-term impact of therapies and lifestyle modifications. Discovering the factors that impact the progression of MR is crucial for efficient patient stratification, treatment scheduling, and risk-benefit analysis. To get a comprehensive understanding of mitral regurgitation and to prioritise patient-centered therapy and wellbeing, it is necessary to evaluate the quality of life that patients feel while dealing with the condition. By determining the financial impact of mitral regurgitation, it may be possible to identify more affordable remedies to the issue. Goals of the Subjective Well-Being (SWB) assessments include happiness, life satisfaction, and overall well-being. The research also delves into the various factors that affect the rising cost of healthcare, including technological advancements, an ageing population, long-term diseases, medicine pricing, the availability of public and commercial health insurance, personal spending habits, and public financing. Mitral regurgitation is a developing condition affecting the heart valves; recent studies have examined its impact on patients' prognoses. The study emphasises the significance of analysing HRQoL since it takes into consideration not only physical health but also mental and social wellbeing. The global problem of affordable healthcare requires a collaborative effort by healthcare providers, insurance companies, and policymakers to find lasting solutions. Understanding the prevalence and incidence of mitral regurgitation is crucial for healthcare resource allocation and organisation. An improvement in medical diagnostic accuracy has the potential to improve treatment results and patient satisfaction. The study also highlights the importance of healthcare economics in decision-making, highlighting the necessity to stay current on surgical techniques and medical technology for the best possible treatment. Understanding the complex aspects of mitral regurgitation leading to deteriorating valvular heart disease, improving patient care, and streamlining diagnostic and treatment processes are all aims of the study. Finding answers to unanswered questions in cardiology is another goal.

LIMITATIONS

It may be costly to invest in research and technology, but doing so could improve treatments for age-related chronic diseases. A number of factors contribute to final prices, including but not limited to: location, labour cost, health insurance, and regulatory frameworks. Prescription drugs can have an impact on pharmacy costs. Reduced healthcare costs may be achieved via value-based treatment, cost-sharing, negotiations, and systemic improvements to delivery. Healthcare cost-effectiveness without compromising quality is an issue for governments, providers, insurers, and individuals alike. Those with degenerative congenital heart disease who had their

mitral valves repaired had a similar survival percentage as those who had them replaced.

REFERENCES

1. Baumgartner, H., Falk, V., Bax, J. J., De Bonis, M., Hamm, C., & Hutter, A. (2021). 2021 ESC/EACTS guidelines for the management of valvular heart disease. European Heart Journal, 42(5), 433-480.
2. Chehab, O., & Zoghbi, W. A. (2020). Secondary mitral regurgitation: Pathophysiology, proportionality, and prognosis. Heart, 106(8), 609–616.
3. Enriquez-Sarano, M., & Basmadjian, A. J. (2023). Current approaches to evaluating mitral regurgitation: A clinical perspective. Journal of the American College of Cardiology, 81(4), 512-523.
4. Iung, B., & Baron, G. (2022). The Euro Heart Survey on valvular heart disease: A focus on patient outcomes. European Journal of Heart Failure, 24(3), 495-507.
5. Iung, B., et al., (2019). A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. European Heart Journal, 24(13), 1231-1243.
6. Kang, D. H., (2020). Early surgery versus conventional treatment in asymptomatic very severe aortic stenosis. Circulation, 121(13), 1502-1509.
7. Lancellotti, P., Pibarot, P., Chambers, J. B., Edvardsen, T., Delgado, V., Dulgheru, R., Garbi, M., Habib, G., & Nieman, K. (2019). Recommendations for the imaging assessment of prosthetic heart valves: A report from the European Association of Cardiovascular Imaging endorsed by the Chinese Society of Echocardiography, the Inter-American Society of Echocardiography, and the Brazilian Department of Cardiovascular Imaging. European Heart Journal–Cardiovascular Imaging, 17(6), 589–590.
8. Mensah, G.A., Roth, G.A., & Fuster, V. (2019), The Global Burden of Cardiovascular Diseases and Risk Factors: 2020 and Beyond. J. Am. Coll. Cardiol. 74, 2529–2532.
9. Meyer, A.C., Drefahl, S., Ahlbom, A., Lambe, M., & Modig, K. (2020), Trends in life expectancy: Did the gap between the healthy and the ill widen or close? BMC Med.18, 41.
10. Nishimura, R. A., & Tajik, A. J. (2020). Valvular heart disease: Current management and future directions. Circulation, 142(20), 1863-1878.
11. Nkomo, V. T., & Gardin, J. M. (2021). The changing epidemiology of valvular heart disease: Insights from recent studies. Heart Rhythm, 18(3), 457-465.
12. Noack, T., Marin Cuartas, M., Kiefer, P., Garbade, J., Pfannmueller, B., & Seeburger, J. (2019). Isolated mitral valve repair in patients with reduced left ventricular ejection fraction. Annals of Thoracic and Cardiovascular Surgery, 25(6), 326–335.
13. Tsang, W. (2019). Recent advances in understanding and managing mitral valve disease. F1000Research, 8, 170.

14. Vahanian, A., & Berthelot-Richer, J. (2021). Advances in the management of valvular heart disease: An update on new technologies and treatment strategies. Heart, 107(14), 1133-1140.